摘要
目的研究比较莫西沙星与左氧氟沙星用于耐多药肺结核的治疗效果。方法采取回顾性研究,研究对象为2015年9月~2017年9月于某院就诊且在疗程内随访成功的的耐多药肺结核病人88例,其中对照组44例接受左氧氟沙星为主,联合乙胺丁醇、吡嗪酰胺、丙硫异烟胺、阿米卡星的治疗方案,疗程2年。观察组44例接受莫西沙星为主,联合用药与对照组相同的治疗方案,疗程2年。分别比较两组病人治疗后空洞缩小率、空洞闭合率、病灶吸收率、痰菌转阴率、治疗成功率和不良反应发生率。结果观察组病灶吸收率、痰菌转阴率及治疗成功率均明显高于对照组(P<0.05);两组病人空洞缩小率、空洞闭合率和不良反应发生率差异均无统计学意义(P>0.05)。结论对于耐多药肺结核的治疗,莫西沙星为主的药物治疗较以左氧氟沙星为主的药物治疗效果好,值得临床应用并推广。
Objective To compare the therapeutic effects of moxifloxacin and levofloxacin on multi drug resistant pulmonary tuberculosis(MDR-TB).Methods A retrospective study was conducted in 88 patients with MDR-TB who were admitted to a hospital from September 2015 to September 2017 and successfully followed during the course of treatment.Among them,44 patients in the control group received levofloxacin as the main treatment,combined with ethambutol,pyrazinamide,prothioanisamine and amikacin.The course of treatment was 2 years.In the observation group,44 patients received moxifloxacin mainly,and the combination therapy was the same as the control group.The course of treatment was 2 years.The cavity reduction rate,cavity closure rate,lesion absorption rate,sputum negative conversion rate,treatment success rate and incidence of adverse reactions were compared between the two groups.Results The lesion absorption rate,sputum negative conversion rate and treatment success rate were significantly higher in the observation group than in the control group(P<0.05).There was no significant difference in the cavity reduction rate,cavity closure rate and incidence of adverse reactions between the two groups(P>0.05).Conclusion For the treatment of MDR-TB,moxifloxacin-based drug therapy is better than levofloxacin-based drug therapy,which is worthy of clinical application and promotion.
作者
刘德平
刘黎
陈慧冬
杨金边
石应元
刘德军
LIU Deping;LIU Li;CHEN Huidong;YANG Jinbian;SHI Yingyuan;LIU Dejun(*Wuhan Infectious Disease Hospital,Hubei430022,China;不详)
出处
《医学动物防制》
2020年第2期141-143,共3页
Journal of Medical Pest Control
基金
武汉市卫生与计划生育委员会科研基金资助项目(WZ17B09).
关键词
莫西沙星
左氧氟沙星
耐多药肺结核
痰菌转阴率
Moxifloxacin
Levofloxacin
Multi drug resistant pulmonary tuberculosis
Sputum negative conversion rate
